NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy |
|
|
| Recruiting | 2/3 | 474 | Europe, Canada, Japan, US, RoW | BIIB059 (litifilimab), litifilimab, Placebo | Biogen, Biogen Idec Research Limited | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | 10/26 | 12/27 | | |
